Comparative efficacy and overall safety of different doses of consensus interferon for treatment of chronic HCV infection: a systematic review and meta-analysis
- First Online:
- 181 Downloads
About one-half of patients with hepatitis C genotype 1 and one-third with genotype 2/3 have treatment failure with peginterferon alpha and ribavirin. Consensus interferon (CIFN) is an option for retreatment of these patients.
To summarize comparative safety and efficacy of different regimens of CIFN for the treatment of patients with chronic hepatitis C infection.
Medline, Scopus, ISI, and Cochran Central Register of Clinical Trials were used.
Study eligibility criteria
Randomized clinical trials (RCTs) were eligible for inclusion in the study.
HIV and HBV seronegative patients with positive HCV-RNA during the 6 months before the start of the study were eligible for inclusion.
Different regimens of CIFN were studied.
Study appraisal and synthesis methods
Studies were appraised based on methods of random sequence generation, allocation concealment, and blinding. The random effects model of DerSimonian and Laird was employed to run the meta-analysis. The end-point was sustained virological response (SVR).
Data of 10 RCTs including 1,600 subjects were extracted. High daily induction dose regimen of CIFN did not yield a higher rate of SVR than low daily induction dose treatment regimen, RR = 0.83 (95% CI 0.58–1.17). A dose of 9 μg thrice weekly (tiw) was associated with a significantly higher rate of SVR compared with 3 μg [RR = 3.14 (95% CI 1.68–5.58)]‹. Withdrawal rate was similar [RR = 1.28 (95% CI 0.65–2.50)] but dose modification was higher in 9 μg [RR = 3.22 (95% CI 1.08–9.60)]. A dose of 18/15 μg tiw was not more effective than 9 μg over a similar treatment duration [RR = 1.02 (95% CI 0. 87–1.19)].
Limitations include inadequate reporting of methodological information and side effects, lack of publication bias assessment due to the small number of studies in each analysis.
High dose daily induction therapy with CIFN is not superior to low dose therapy in terms of SVR. It seems that 9 μg tiw is the optimal treatment dose of CIFN for treatment of HCV infection. Optimal duration and safety profile of CIFN therapy have yet been elucidated.
KeywordsConsensus interferon Induction therapy High dose Low dose Meta-analysis Systematic review
- 1.Ahmadipour MH, Alavian SM, Amini S, Azadmanesh K (2005) Hepatitis C virus genotypes. Hepat Mon 5(3):77–82Google Scholar
- 5.Berenguer J, Alvarez-Pellicer J, Martin PM, Lopez-Aldeguer J, Von-Wichmann MA, Quereda C et al (2009) Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 50(2):407–413CrossRefPubMedGoogle Scholar
- 9.Miyake Y, Takaki A, Iwasaki Y, Yamamoto K (2010) Meta-analysis: interferon-alpha prevents the recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma. J Viral Hepat 17(4):287–292Google Scholar
- 13.Lin R, Roach E, Zimmerman M, Strasser S, Farrell GC (1995) Interferon alfa-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates. Results of the first multicentre Australian trial. Australia Hepatitis C Study Group. J Hepatol 23(5):487–496CrossRefPubMedGoogle Scholar
- 16.Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G et al (1998) Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 352(9138):1426–1432CrossRefPubMedGoogle Scholar
- 18.Ferenci P, Formann E, Laferl H, Gschwantler M, Hackl F, Brunner H et al (2006) Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naive patients with chronic hepatitis C genotype 1 infection. J Hepatol 44(2):275–282CrossRefPubMedGoogle Scholar
- 19.Bosques-Padilla F, Trejo-Estrada R, Campollo-Rivas O, Cortez-Hernandez C, Dehesa-Violante M, Maldonado-Garza H et al (2003) Peginterferon alfa-2a plus ribavirin for treating chronic hepatitis C virus infection: analysis of Mexican patients included in a multicenter international clinical trial. Ann Hepatol 2(3):135–139PubMedGoogle Scholar
- 26.Borenstein M, Hedges LV, Higgins JPT, Rothstein HR (2009) Introduction to meta-analysis, 1st edn. Wiley, LondonGoogle Scholar
- 27.Petitti DB (2000) Meta-analysis, decision analysis, and cost-effectiveness analysis: methods for quantitative synthesis in medicine, 2nd edn. Oxford University Press, New YorkGoogle Scholar
- 29.Alaimo G, Di Marco V, Ferraro D, Di Stefano R, Porrovecchio S, D'Angelo F et al (2006) Different doses of consensus interferon plus ribavirin in patients with hepatitis C virus genotype 1 relapsed after interferon monotherapy: a randomized controlled trial. World J Gastroenterol 12(42):6861–6864PubMedGoogle Scholar
- 34.Heathcote EJ, James S, Mullen KD, Hauser SC, Rosenblate H, Albert DG Jr (1999) Chronic hepatitis C virus patients with breakthroughs during interferon treatment can successfully be retreated with consensus interferon. The Consensus Interferon Study Group. Hepatology 30(2):562–566CrossRefPubMedGoogle Scholar
- 37.Jensen DM, Krawitt EL, Keeffe EB, Hollinger FB, James SP, Mullen K et al (1999) Biochemical and viral response to consensus interferon (CIFN) therapy in chronic hepatitis C patients: effect of baseline viral concentration. Consensus Interferon Study Group. Am J Gastroenterol 94(12):3583–3588CrossRefPubMedGoogle Scholar
- 40.Keeffe EB, Dusheiko GM, Tong MJ, Hollinger FB, Heathcote EJ, McHutchison J et al (1999) Genotype does not affect pattern of HCV RNA decrease among responders during interferon treatment of chronic hepatitis C. Consensus Interferon Study Group. Cytokines Cell Mol Ther 5(4):211–216PubMedGoogle Scholar
- 53.MacNicholas R, Norris S (2010) Review article: optimizing SVR and management of the haematological side effects of peginterferon/ribavirin antiviral therapy for HCV—the role of epoetin, G-CSF and novel agents. Aliment Pharmacol Ther 31(9):929–937Google Scholar
- 55.Hopewell S, Loudon K, Clarke MJ, Oxman AD, Dickersin K (2009) Publication bias in clinical trials due to statistical significance or direction of trial results. Cochrane Database Syst Rev (1):MR000006Google Scholar